Table 5.

Network meta-analyses for grade 3-5 AEs.

Atezolizumab + Bevacizumab
0.92 (0.64, 1.32)	Brivanib
1.55 (1.02, 2.36)	1.69 (1.13, 2.52)	Donafenib
0.79 (0.48, 1.29)	0.86 (0.53, 1.39)	0.51 (0.30, 0.86)	Erlotinib + Sorafenib
0.69 (0.24, 1.98)	0.75 (0.27, 2.15)	0.45 (0.15, 1.30)	0.88 (0.29, 2.65)	GEMOX + Sorafenib
0.67 (0.45, 0.98)	0.73 (0.50, 1.06)	0.43 (0.28, 0.66)	0.85 (0.51, 1.40)	0.96 (0.34, 2.78)	Lenvatinib
0.52 (0.34, 0.79)	0.57 (0.38, 0.84)	0.33 (0.21, 0.52)	0.66 (0.39, 1.11)	0.75 (0.26, 2.18)	0.78 (0.51, 1.19)	Linifanib
3.35 (2.21, 5.07)	3.65 (2.45, 5.44)	2.16 (1.38, 3.38)	4.26 (2.52, 7.19)	4.84 (1.66, 14.09)	5.01 (3.28, 7.66)	6.44 (4.11, 10.08)	Nivolumab
1.11 (0.60, 2.06)	1.21 (0.66, 2.22)	0.71 (0.37, 1.35)	1.41 (0.70, 2.84)	1.60 (0.50, 5.09)	1.66 (0.89, 3.09)	2.13 (1.12, 4.04)	0.33 (0.17, 0.63)	Placebo
0.76 (0.49, 1.19)	0.83 (0.54, 1.27)	0.49 (0.31, 0.79)	0.97 (0.56, 1.68)	1.10 (0.38, 3.25)	1.14 (0.73, 1.80)	1.47 (0.92, 2.35)	0.23 (0.14, 0.37)	0.69 (0.36, 1.34)	Sintilimab + Bevacizumab
1.01 (0.77, 1.32)	1.10 (0.86, 1.40)	0.65 (0.47, 0.89)	1.28 (0.84, 1.94)	1.45 (0.52, 4.03)	1.51 (1.14, 2.00)	1.94 (1.41, 2.66)	0.30 (0.22, 0.41)	0.91 (0.52, 1.59)	1.32 (0.93, 1.88)	Sorafenib
0.92 (0.70, 1.20)	1.00 (0.78, 1.28)	0.59 (0.43, 0.81)	1.17 (0.77, 1.77)	1.32 (0.48, 3.67)	1.37 (1.03, 1.82)	1.76 (1.28, 2.42)	0.27 (0.2, 0.38)	0.83 (0.47, 1.45)	1.2 (0.84, 1.71)	0.91 (0.89, 0.93)	Sunitinib

AEs, adverse events.